

### Presentation of Results for the year ended 31<sup>st</sup> March 2007

7th June 2007

### **Cautionary Statement**

This presentation contains forward looking statements that are subject to risk factors associated with, amongst other things, the economic and business circumstances occurring from time to time in the countries and sectors in which Johnson Matthey operates. It is believed that the expectations reflected in these statements are reasonable but they may be affected by a wide range of variables which could cause actual results to differ materially from those currently anticipated.



Introduction

Neil Carson
Chief Executive

### 2006/07 Highlights

- Strong growth in sales and operating profit
- Underlying earnings per share up 12%
- Environmental concerns and energy prices drive long term growth
- New divisions from 1<sup>st</sup> April 2007





### Johnson Matthey

**Financial Review** 

John Sheldrick
Group Finance Director

### **Summary Results**

	2007	2006	
	£m	£m	%
Revenue	6,152	4,574	+34
Sales excluding precious metals	1,454	1,159	+25
Profit before tax	226.5	191.5	+18
Total earnings per share	96.9p	<b>70.8</b> p	+37

#### Before one-off items (including discontinued operations' results):

**Dividend** 

Profit before tax	242.6	219.8	+10
Earnings per share	81.2p	<b>72.7</b> p	+12

33.6p



+12


**30.1p** 

### **Operating Profit**

	2007	2006	2007 at 2006		2006
			exchange rates		
Continuing Businesses	£m	£m	%	£m	%
Catalysts	148.8	134.2	+11	152.7	+14
<b>Precious Metal Products</b>	85.3	62.2	+37	87.1	+40
Pharmaceutical Materials	35.5	33.8	+5	36.2	+7
Corporate	(17.2)	(16.8)		(17.2)	
Operating profit	252.4	213.4	+18	258.8	+21



### **US Dollar Exchange Rate**





### Return on Sales Excluding Precious Metals

	Sales excl. PMs		ROS		
	2007	2006	Growth	2007	2006
<b>Continuing Businesses</b>	£m	£m	%	%	%
Catalysts	1,036	<b>786</b>	+32	14.4	17.1
<b>Precious Metal Products</b>	290	245	+18	29.4	25.3
<b>Pharmaceutical Materials</b>	129	127	+1	27.6	26.6
	1,454	1,159	+25	17.4	<u> 18.4</u>



### **Substrate Costs**

Autocatalyst £3 - £10




**CSF** 

£100 - £120



**HDD** 

Flow through £60 Filter system £300





### **Taxation**

**Total tax** 

**Ceramics Division Tax on profit on sale** 

Income tax expense

**Underlying tax rate** 

2007	2006	
£m	£m	
71.5	62.5	
(5.7)	(7.8)	
(1.1)	-	
64.7	54.7	

28.6%<sup>1</sup>

29.3%<sup>2</sup>



<sup>&</sup>lt;sup>1</sup> Excl. Ceramics <sup>2</sup> Division

<sup>&</sup>lt;sup>2</sup> Incl. Ceramics Division

### **Capital Expenditure to Depreciation**

Year to 31st March 2007

Capital		Capex/
<b>Expenditure</b>	<b>Depreciation</b>	<b>Depreciation</b>
£m	£m	(times)

Catalysts
Precious Metal Products
Pharmaceutical Materials
Discontinued / Other

**Total Group** 

91.5	46.0	2.0
11.2	13.4	8.0
10.7	10.5	1.0
6.4	7.6	8.0
119.8	77.5	1.5



### **Change in Net Debt**

Cash flow from operations
Interest / dividends
Capex / asset sales
Acquisitions / disposals
Shares bought
Net cash flow
Debt disposed / acquired
Exchange
Change in net debt

2007	2006
£m	£m
159	212
(92)	(74)
(122)	(115)
119	(24)
(50)	_(26)
14	(27)
19	(1)
14	_(13)_
47	(42)



#### **Return on Investment**

	2007	2006
	£m	£m
Operating profit	252 <sup>1</sup>	235 <sup>2</sup>
Average assets:		
Equity	1,061	987
Net debt	388	391
Total investment	1,450	1,378
Pre-tax ROA	17.4%	17.0%
Return on invested capital	12.4%	12.0%
WACC	8%	8%

<sup>&</sup>lt;sup>1</sup> Continuing businesses



<sup>&</sup>lt;sup>2</sup> Including Ceramics but before one-off items

### **Capital**

**Net debt** 

**Equity** 

**Capital employed** 

Gearing (net debt / equity)

412
1,045
1,457

33.8% 39.4%






### Johnson Matthey

**Operating Review** 

Neil Carson
Chief Executive

### **Catalysts Division**

- Profits up 11%
- Both ECT and PCT perform well



### Estimated Light Vehicle Sales and Production

Year to	31 <sup>st</sup>	March
---------	------------------	-------

	2007	2006	change
North America	millions	millions	%
Sales	19.3	19.7	-2.0%
Production	14.9	15.9	-6.3%
Europe			
Sales	21.3	20.6	+3.4%
Production	21.1	20.7	+1.9%
Asia			
Sales	16.4	15.2	+7.9%
Production	25.4	23.2	+9.5%
Global			
Sales	66.3	64.5	+2.8%
Production	66.9	64.9	+3.1%

**Source: Global Insight** 



- Strong top line growth
- Good growth in Europe, particularly in diesel catalysts and CSFs
- Good autocatalyst growth in Asia, particularly in China and Japan
- North America benefits from new diesel market
- Good contribution from HDD sales to OEMs
- Further strong sales growth expected in 2007/08



#### **Light Duty Diesel**

- Diesel cars now more than 50% of European market
- All diesel vehicles in Europe require a diesel oxidation catalyst. Johnson Matthey has leading share
- Our major customers are increasingly fitting CSFs ahead of legislation
- Additional CSF facility at Royston opens this year
- US initiative to increase fuel efficiency boosts interest in diesels




### **Light Duty Vehicles in Asia**

- Asia will provide most of growth in light duty vehicle production
- Capacity increased in Japan. Johnson Matthey gaining share
- New plant in South Korea opens this year
- Good growth in China. Leading share of Indian and Malaysian markets



HDD on-road regulation development




New models	All models
01-Oct-05	01-Oct-06
01-Oct-08	01-Oct-09
01-Jan-07	01-Jan-07
01-Jan-10	01-Jan-10
01-Oct-03	01-Sep-04
01-Oct-04	01-Sep-05
01-Oct-05	01-Sep-07
end 2009/2010	2010/2011
2008	
2010	
2010 (or earlier?)	
01-Jan-06	01-Jan-08
2009	
	01-Oct-05 01-Jan-07 01-Jan-10 01-Oct-03 01-Oct-04 01-Oct-05 end 2009/2010 2008 2010 2010 (or ear



### HDD Market Size Forecast All Heavy Duty Vehicles Sold

#### '000 vehicles



■ North America ■ Europe ■ Japan

**Europe and Japan > 6 tonnes** 

US classes 4-7 and 8

**Source: JD Power Global Commercial Vehicle Forecast** 



**Heavy Duty Diesel Summary** 

- Market size \$700 million p.a. (ex pms) in 2008
- Further tightening of legislation in Europe, US and Japan by 2010
- Legislation expected in China, India, South Korea and Brazil
- Non road regulation starts in 2011
- Projected market size of \$3 billion p.a. (ex pms) by end of 2014



# Process Catalysts and Technologies


- Good growth in sales and profits
- AMOG well ahead. Good demand from methanol producers
- Very strong start for DPT. Several major contracts won in China
- Fine chemical and catalyst businesses performed well



# Process Catalysts and Technologies Future Business Drivers

High oil price brings 3 important new drivers to JM's PCT business

- More heavy / dirty crude will be processed
- Expensive oil will be used to make high value products. Gas and coal will increasingly be used to make chemicals and fuels
- Efforts to use less oil and concerns about climate change lead to low carbon era





# Process Catalysts and Technologies Future Business Drivers

- Heavy / dirty oil requires more hydrogen to crack.
   Contaminants removed by high tech absorbents
- Syngas is first step in gas to products. DPT is a leader in process design and licensing
- CO<sub>2</sub> is new pollutant



### **Fuel Cells**


- Fuel Cells will also benefit from interest in low carbon and low emission technologies
- Major car companies announce fuel cell cars
- Good growth in sales of membrane electrode assemblies for direct methanol fuel cells
- Net expense reduced by £0.8 million to £7.3 million






### **Precious Metal Products**

- Profits up 37%
- Buoyant pgm markets and good growth in manufacturing businesses




### **Platinum and Palladium Prices**





### **Rhodium Price**



#### **Precious Metal Products**

- Strong growth in marketing and distribution business
- Second half of 2006/07 benefited from profits on minor metals
- Market conditions remain favourable
- Further growth expected in 2007/08 primarily in the first half




### Precious Metal Products Manufacturing Businesses

- Good growth in pgm fabrication businesses, particularly in medical products in the US
- New catalyst market for abatement of N<sub>2</sub>O (a powerful greenhouse gas)
- Good progress in pgm refining
- Continued growth in Colour Technologies business



### **Pharmaceutical Materials**

- Profits up 5%
- Good recovery in US operations



### Pharmaceutical Materials Operations

- Good recovery in US
- Growth in US sales of APIs for controlled drugs (ADDERALL®, methylphenidate and specialist opiates)
- Good recovery in US contract research business
- Bulk opiate sales in Europe below last year
- Specialist opiate sales in Europe continue to show good growth



### Pharmaceutical Materials Future Prospects

- Continued growth in generic pain killers
- Market for platinum anticancer drugs continues to expand
- NDA filed for Satraplatin. If successful, GPC Biotech hope to launch in 2007
- Launch of generic ADDERALL XR® agreed for April 2009
- Several new prostaglandin products to be launched in the next few years



#### **New Divisional Structure**

From 1<sup>st</sup> April 2007

#### **Johnson Matthey**

### **Environmental Technologies Division**

**Emission Control Technologies (ECT)** 

Process Technologies (AMOG, DPT, Tracerco)

**Fuel Cells** 

### **Precious Metal Products Division**

Platinum Marketing and Distribution

**Noble Metals** 

**Pgm Refining** 

**Colour Technologies** 

**Gold and Silver** 

### Fine Chemicals & Catalysts Division

**Pharmaceutical Materials** 

**Catalysts and Chemicals** 

**Research Chemicals** 



## New Divisions Restated Sales and Operating Profit

#### 2007

<b>Environmental Technologies</b>	
<b>Precious Metal Products</b>	
Fine Chemicals & Catalysts	
Corporate	
Continuing businesses	

	Sales	Operating	
Revenue	ex. PMS	Profit	
£m	£m	£m	
4.004	000	400.4	
1,864	896	120.1	
3,824	290	85.3	
463	268	64.2	
		(17.2)	
6,152	1,454	252.4	



### Outlook Environmental Technologies

- Further strong growth in sales ex pms
- Full year benefit of HDD sales to OEMs
- Continued growth in diesel products in Europe and autocatalysts in Asia
- Overall, we expect ECT to achieve double digit growth in sales and operating profits in 2007/08
- Process Technologies should also perform well with continued strong demand across its product range



### Outlook Other Divisions

- Market conditions for pgms remain favourable
- PMP should achieve further growth in 2007/08 although not as strong as 2006/07
- Fine Chemicals & Catalysts expected to achieve steady growth in 2007/08
- US dollar weakness may cause adverse exchange translation



### **Outlook** Summary

- Overall we expect the continuing businesses to perform well in 2007/08 with very good growth in PBT
- Growth in EPS will be 4 to 5% lower than PBT growth due to dilutive effect of sale of Ceramics
- Medium term outlook remains very encouraging with substantial growth opportunities for Environmental Technologies and good prospects for the other two divisions



